Oxford BioDynamics plc (OBD) Ordinary 1p Shares
Share news, reports & tips
31 August 2021 12:48
(Sharecast News) - Oxford BioDynamics has been awarded an FNIH Partnership for Accelerating Cancer Therapies (PACT) grant, it announced on Tuesday, to use its 'EpiSwitch' diagnostic platform for...
31 March 2021 08:05
(Sharecast News) - Biotechnology company Oxford BioDynamics has signed a supply and resale agreement with US firm Agilent Technologies for the manufacture and sale of its new EpiSwitch Explorer Array Kit.
14 December 2020 09:29
(Sharecast News) - Biotechnology company Oxford BioDynamics appointed a new chairman on Monday.
16 June 2020 13:15
(Sharecast News) - Biotechnology company Oxford BioDynamics reported a fall in revenue to £0.2m in its interim results on Tuesday, from £0.6m a year earlier.
14 May 2020 16:01
(Sharecast News) - Oxford BioDynamics revealed on Thursday that interim chairman Stephen Diggle had acquired 30,000 ordinary shares in the AIM-listed biotechnology firm via his interest in Vulpes Testudo Fund.
11 December 2019 16:11
(Sharecast News) - Oxford Biodynamics revealed on Wednesday that interim chairman Stephen Diggle had purchased 18,309 ordinary shares in the AIM-listed biotechnology firm.
Company announcements Announcements
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2022. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.